← 返回

IL-2/GM-CSF 通过 PI3K/AKT 和 ERK1/2 通路增强 CAR-T 细胞中 CXCR3 表达

英文原题:IL-2/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K/AKT and ERK1/2 pathways.

查看英文原题

IL-2/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K/AKT and ERK1/2 pathways.

PubMed 2022/12/06(内容时间) J Cancer Res Clin Oncol Q2 · IF 3.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

多因素扩增方案可在体外有效提高活化 CAR-T 细胞表面 CXCR3 的表达,并在体内增强 CAR-T 细胞的趋化能力,从而显著抑制肝癌生长。

研究思路结论见上方概要

肿瘤内高淋巴细胞浸润是肿瘤免疫治疗取得良好效果的基本要求;C-X-C基序趋化因子受体3(CXCR3)是淋巴细胞向肿瘤组织趋化的重要因子。肿瘤微环境可表现出多种细胞因子抑制或促进抗肿瘤免疫。白细胞介素(IL)-2和粒细胞巨噬细胞集落刺激因子(GM-CSF)均有助于调节肿瘤微环境中的免疫抑制。然而,IL-2和GM-CSF对T细胞表面CXCR3表达的影响及其机制尚不清楚。在此,我们探讨了多细胞因子对CAR-T 细胞(CAR-T 细胞)中CXCR3表达的影响以及对HuH-7原位肝细胞癌的影响。

探讨细胞因子IL-2和GM-CSF对CAR-T 细胞CXCR3表达及趋化作用的影响。

外周血单个核细胞(PBMCs)被分离,随后使用CD3免疫磁珠进行纯化。细胞分为三组。使用CD3/CD28抗体激活24小时后,T细胞使用慢病毒载体pGC-SV40-EGFP-GPC3-CAR进行转染。使用三种培养方法扩增转染的T细胞。方法“A”是将T细胞与CD3/CD28抗体共孵育;方法“B”是使用CD3/CD28抗体和终浓度为1000 U/ml的IL-2;方法“C”是在方法B的基础上添加终浓度为1000 U/ml的GM-CSF。通过western blot测定MAPK和PI3K/AKT的磷酸化。通过免疫荧光和免疫组化检测CAR-T 细胞对Huh-7 HCCIA原位的趋化作用。

CD3/CD28/IL-2/GM-CSF组合在体外对刺激活化的CAR-T 细胞增殖和CXCR3表达最为有效;CD3/CD28/IL-2通过激活PI3K/APK通路诱导CAR-T 细胞表达CXCR3,GM-CSF通过激活ERK1/2而非p38 MAPK信号通路诱导CAR-T 细胞中CXCR3的表达。CXCR3高表达的CAR-GPC3-T细胞对HuH原位肝细胞癌的趋化能力增强,并显著抑制裸鼠肝脏中原位肿瘤的生长。

展开英文摘要原文

To investigate the effects of cytokines IL-2 and GM-CSF on CXCR3 expression and chemotaxis of CAR-T cells.

High lymphocyte infiltration within the tumor is a basic requirement for good results in tumor immunotherapy; C-X-C motif chemokine receptor 3 (CXCR3) is an important factor for the chemotaxis of lymphocytes to tumor tissues. The tumor microenvironment can exhibit diverse cytokine suppression or promote antitumor immunity. Both interleukin (IL)-2 and granulocyte macrophage colony-stimulating factor (GM-CSF) contribute to the regulation of immunosuppression in the tumor microenvironment. However, the effects of IL-2 and GM-CSF on CXCR3 expression on the T cell surface and its mechanisms are not well understood. Here, we explored the effects of polycytokines on CXCR3 expression in chimeric antigen receptor T cells (CAR-T cells) and on HuH-7 in situ hepatocellular carcinoma.

Peripheral blood mononuclear cells (PBMCs) were isolated, followed by purifying using CD3 immunomagnetic beads. Cells were divided into three groups. After 24h of activation using CD3/CD28 antibody, T cells were transfected using lentiviral vector, pGC-SV40-EGFP-GPC3-CAR. Three culture methods were used to amplify the transfected T cells. Method 'A' was to incubate T cells with CD3/CD28 antibody; method 'B' was with CD3/CD28 antibody and IL-2 at a final concentration of 1000 U/ml; method 'C' was with method B in addition of GM-CSF at a final concentration of 1000 U/ml. The phosphorylation of MAPK and PI3K/AKT was determined by western blot. The chemotaxis effect of CAR-T cells on Huh-7 HCCIA in situ was assayed by immunofluorescence and immunohistochemistry.

The CD3/CD28/IL-2/GM-CSF combination is the most potent for stimulating activated CAR-T cell proliferation and CXCR3 expression in vitro; CD3/CD28/IL-2 induces CAR-T cell expression of CXCR3 through the activation of the PI3K/APK pathway and GM-CSF induces CXCR3 expression in CAR-T cells through the activation of ERK1/2 rather than the p38 MAPK signaling pathway. CAR-GPC3-T cells with high CXCR3 expression showed increased chemotaxis ability to HuH in situ hepatocellular carcinoma, and considerably inhibited the growth of in situ tumors in nude mouse livers.

A multi-factorial amplification protocol can effectively improve CXCR3 expression on the surface of activated CAR-T cells in vitro, as well as enhance the chemotaxis ability of CAR-T cells in vivo, which significantly inhibit the growth of liver cancer.

论文信息

作者
Liu L、Cheng Y、Zhang F、Chen J、Tian P、Shi W、Zhou F、Yang M
第一作者单位
College of Medical Technology, Anhui Medical College, Hefei, China.China
通讯作者单位
Department of Cell Center, The 901th Hospital of PLA Joint Logistic Support Force, Hefei, China. iul1@163.com.China
期刊
Journal of cancer research and clinical oncology2023 Aug
原文标识
PubMed 36474002 · DOI 10.1007/s00432-022-04509-w